CollPlant Biotechnologies Ltd. (CLGN)
| Market Cap | 88.25M |
| Revenue (ttm) | 1.21M |
| Net Income (ttm) | -13.75M |
| Shares Out | 11.09M |
| EPS (ttm) | -1.30 |
| PE Ratio | n/a |
| Forward PE | 4.92 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 6,447 |
| Open | 8.55 |
| Previous Close | 8.34 |
| Day's Range | 7.82 - 8.55 |
| 52-Week Range | 7.50 - 23.00 |
| Beta | 1.14 |
| Analysts | Buy |
| Price Target | 21.93 (+175.5%) |
| Earnings Date | May 25, 2022 |
About CLGN
CollPlant Biotechnologies Ltd., a regenerative and aesthetic medicine company, focuses on three-dimensional (3D) bioprinting of tissues and organs, and medical aesthetics in the United States, Canada, and Europe. Its products are based on recombinant type I human collagen that is produced with its proprietary plant based genetic engineering technology. The company's products include BioInks for 3D printing of tissues and organs; dermal filler and soft tissue fillers for treating wrinkles; 3D Bioprinted breast implants for regeneration of breast... [Read more...]
Financial Performance
Financial StatementsAnalyst Forecast
According to 7 analysts, the average rating for CLGN stock is "Buy." The 12-month stock price forecast is 21.93, which is an increase of 175.50% from the latest price.
News
CollPlant Biotechnologies Provides Business Updates and First Quarter 2022 Financial Results
Co-development of rhCollagen-based dermal and soft tissue filler products with AbbVie is advancing according to plan Launch of large animal study for Company's 3D bioprinted regenerative breast implant ...
CollPlant CEO Yehiel Tal to Moderate ISBF's virtual event on Biofabrication of Microphysiological Systems for Drug Di...
REHOVOT, Israel , April 25, 2022 /PRNewswire/ -- CollPlant (Nasdaq: CLGN), a regenerative and aesthetics medicine company developing innovative technologies and products for tissue regeneration and orga...
New Strong Sell Stocks for April 22nd
BBBY, CLGN, and ADAP have been added to the Zacks Rank #5 (Strong Sell) List on April 22, 2022
CollPlant To Present at the Aesthetics Innovation Summit 2022
REHOVOT, Israel , April 13, 2022 /PRNewswire/ -- CollPlant (NASDAQ: CLGN), a regenerative and aesthetics medicine company developing innovative technologies and products for tissue regeneration and orga...
CollPlant Biotechnologies Provides Business Updates and Fiscal Year 2021 Financial Results
REHOVOT, Israel, March 24, 2022 /PRNewswire/ -- CollPlant Biotechnologies (NASDAQ: CLGN), a regenerative and aesthetic medicine company developing innovative technologies and products for tissue regener...
CELLINK and CollPlant Enter a Collaboration Agreement to Explore Future Large-Scale Production of CollPlant's Regener...
GOTHENBURG, Sweden and REHOVOT, Israel, Feb. 16, 2022 /PRNewswire/ -- Today, CELLINK, a BICO Group company (Nasdaq Stockholm: BICO) and a global leader in developing 3D bioprinting technologies which is...
CollPlant Issues Letter to Shareholders
REHOVOT, Israel, Jan. 5, 2022 /PRNewswire/ -- CollPlant Biotechnologies (Nasdaq: CLGN), a regenerative and aesthetic medicine company developing innovative technologies and products for tissue regenerat...
CollPlant Announces Publication Highlighting its rhCollagen-based Photocurable Dermal Filler in the Plastic and Recon...
Preclinical modeling demonstrates potential for filler to enhance cell proliferation and new tissue regeneration for aesthetic medicine applications REHOVOT, Israel, Dec. 2, 2021 /PRNewswire/ -- CollPla...
CollPlant Biotechnologies Provides Business Updates and Third Quarter 2021 Financial Results
REHOVOT, Israel, Nov. 18, 2021 /PRNewswire/ -- CollPlant Biotechnologies (NASDAQ: CLGN), a regenerative and aesthetic medicine company developing innovative technologies and products for tissue regenera...
CollPlant Announces Commercial Launch of BioInk Platform with Collink.3D™ for Use in 3D Bioprinting of Human Tissues,...
REHOVOT, Israel, Nov. 15, 2021 /PRNewswire/ -- CollPlant Biotechnologies (Nasdaq: CLGN), a regenerative and aesthetics medicine company developing innovative technologies and products for tissue regener...
CollPlant to Present at Dawson James Small Cap Growth Conference on October 21st
REHOVOT, Israel, Oct. 14, 2021 /PRNewswire/ - CollPlant Biotechnologies (Nasdaq: CLGN), a regenerative and aesthetics medicine company developing innovative technologies and products for tissue regenera...
CollPlant's rhCollagen BioInk Used by Technion Researchers to Develop 3D Bioprinted Vascularized Tissue Constructs
REHOVOT, Israel, Oct. 11, 2021 /PRNewswire/ -- CollPlant Biotechnologies (Nasdaq: CLGN), a regenerative and aesthetics medicine company developing innovative technologies and products for tissue regener...
CollPlant to Present at Fall Harvest - Best Ideas from the Buy-Side on October 5, 2021
REHOVOT, Israel, Sept. 30, 2021 /PRNewswire/ -- CollPlant Biotechnologies (NASDAQ: CLGN), a regenerative and aesthetics medicine company developing innovative technologies and products for tissue regene...
CollPlant CEO Yehiel Tal to Discuss Emerging Uses of rhCollagen in Aesthetic and Regenerative Medicine at NANO.IL.202...
REHOVOT, Israel, Sept. 27, 2021 /PRNewswire/ -- CollPlant (NASDAQ: CLGN), a regenerative and aesthetics medicine company developing innovative technologies and products for tissue regeneration and organ...
CollPlant CEO Yehiel Tal elected to the Board of Directors of the International Society for Biofabrication (ISBF)
REHOVOT, Israel, Sept. 9, 2021 /PRNewswire/ -- CollPlant (NASDAQ: CLGN), a regenerative and aesthetics medicine company developing innovative technologies and products for tissue regeneration and organ ...
CollPlant To Present at the H.C. Wainwright Annual Global Investment Conference in September
REHOVOT, Israel, Sept. 7, 2021 /PRNewswire/ -- CollPlant (NASDAQ: CLGN), a regenerative and aesthetics medicine company developing innovative technologies and products for tissue regeneration and organ ...
CollPlant Appoints Medical Aesthetics Veteran Alisa Lask to Board of Directors
REHOVOT, Israel, Aug. 19, 2021 /PRNewswire/ -- CollPlant (Nasdaq: CLGN), a regenerative and aesthetic medicine company developing innovative technologies and products for tissue regeneration and organ m...
Recap: CollPlant Biotechnologies Q2 Earnings
Shares of CollPlant Biotechnologies (NASDAQ:CLGN) were unchanged after the company reported Q2 results. Quarterly Results Earnings per share fell 25.00% year over year to ($0.25), which missed the estim...
CollPlant Biotechnologies Provides Business Updates and Second Quarter 2021 Financial Results
REHOVOT, Israel, Aug. 19, 2021 /PRNewswire/ -- CollPlant (Nasdaq: CLGN), a regenerative and aesthetic medicine company developing innovative technologies and products for tissue regeneration and organ m...
CollPlant Biotechnologies to Present on the Use of Collagen BioInk as a Platform for 3D Bioprinting of Tissues and Or...
REHOVOT, Israel, Aug. 16, 2021 /PRNewswire/ - CollPlant (Nasdaq: CLGN), a regenerative and aesthetic medicine company developing innovative technologies and products for tissue regeneration and organ ma...
Why 3D Systems, CollPlant BioTechnologies, and Stratasys Stocks Soared Today
Five months ago, 3D Systems promised to expand into the "nascent industry" of printing entire human body parts. Today, it's doing just that.
CollPlant Announces Effectiveness of Uplisting to the Nasdaq Global Market®; Ordinary Shares Replace ADSs
REHOVOT, Israel, June 4, 2021 /PRNewswire/ -- CollPlant (NASDAQ: CLGN), a regenerative and aesthetic medicine company, announced today the uplisting of its ordinary shares to the Nasdaq Global Select Ma...
CollPlant Biotechnologies Reports First Quarter 2021 Financial Results with Record Revenues of $14.5 Million
REHOVOT, Israel, May 27, 2021 /PRNewswire/ -- CollPlant (NASDAQ: CLGN), a regenerative and aesthetic medicine company, today announced financial results for the first quarter ended March 31, 2021 and pr...
CollPlant Announces Uplisting to the Nasdaq Global Market® and Transition to Trading of Ordinary Shares Instead of ADSs
REHOVOT, Israel, May 25, 2021 /PRNewswire/ -- CollPlant (NASDAQ: CLGN), a regenerative and aesthetic medicine company, announced that its ordinary shares have been approved for trading on the Nasdaq Glo...
CollPlant Biotechnologies Ltd. Sponsored ADR (CLGN) Outpaces Stock Market Gains: What You Should Know
CollPlant Biotechnologies Ltd. Sponsored ADR (CLGN) closed at $14.68 in the latest trading session, marking a +1.91% move from the prior day.